The FDA granted accelerated approval for Clovis Oncology's (CLVS) rucaparib drug.
Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.
Clovis Oncology (CLVS) stock is dipping on Wednesday as an FDA advisory committee voted against approving the company's lung cancer drug rociletinib yesterday.
An FDA advisory committee delivers a brutal beatdown of Clovis' lung cancer drug rociletinib. It could cost Clovis' CEO his job.